A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Open to Enrollment
This clinical trial is for men and women with relapsed or relapsed and refractory Multiple Myeloma. The study is evaluating an experimental drug called Ibrutinib (PCI-32765), in combination with Carfilzomib, which is currently FDA approved for relapsed and refractory multiple myeloma.
Ibrutinib is a type of drug called a “kinase inhibitor”. “Kinases” are proteins inside cells that help cells live and grow. The specific kinase inhibited or “blocked” by ibrutinib is believed to help blood cancer cells live and grow. By inhibiting the activity of this specific kinase, it is possible that the ibrutinib may kill the cancer cells or stop them from growing. This investigational drug being tested and is not approved for sale in any country.
Carfilzomib is a proteasome inhibitor, proteasomes are enzymes in cells that play a role in the cell growth and regulation by controlling the breakdown of enzymes. Carfilzomib blocks the activity of proteasomes and disrupts the processes related to growth and survival of cancer cells. Carfilzomib is approved by the FDA for the treatment of relapsed and refractory multiple myeloma.
The study has 2 parts (participants will be enrolled in part 1 at this time).
Part 1 tests different doses of ibrutinib and carfilzomib together to study what dose to use in part 2. Part 2 will study the effects of the treatment. All subjects will receive carfilzomib, only half of the subjects will receive ibrutinib, to test if there is a benefit to adding ibrutinib to carfilzomib treatment.
Participants will take ibrutinib daily on every day of 28 day cycles, beginning on cycle 1 day 8. Participants will continue on study treatment for as long as they are responding to therapy and not experiencing unacceptable side effects.
- Men and women age 18 and older
- Multiple Myeloma
- Relapsed/refractory after at least 2 lines of standard therapy including:
- bortezomib (Velcade) and an immunomodulator drug
- Detailed eligibility reviewed when you contact the study team
Linda Tegnestam, R.N.
Phone: (212) 746-1480
Kathleen Pogonowski, R.N.
Phone: (212) 746-6738
Disease Status and/or Stage
Relapsed or Refractory Multiple Myeloma
WCMC IRB # 1311014525
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.